Canine Atopic Dermatitis Industry Expected to Reach $4.09 Billion by 2029 at 10.3% CAGR

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

Canine Atopic Dermatitis Market Value Projection: How Much Will the Market Size by 2025?
In recent years, there has been a rapid surge in the market size for canine atopic dermatitis. The market size, recorded at $2.49 billion in 2024, is predicted to expand to $2.76 billion in 2025, marking a compound annual growth rate (CAGR) of 10.6%. Key factors fueling this growth over the historical period include an uptick in pet ownership, heightened consciousness of pet health, a rising incidence of allergy-related conditions in dogs, an increase in spending on veterinary healthcare, and the enhanced availability of pet insurance.

What Will Be the Market Growth Forecat for Canine Atopic Dermatitis in 2029?
We can anticipate a swift expansion in the market size of canine atopic dermatitis in the upcoming years. It's projected to increase to $4.09 billion in 2029 with a compound annual growth rate (CAGR) of 10.3%. This growth during the predicted period can be credited to the rising acceptance of telemedicine in animal care, the escalating demand for personalized pet care solutions, increased funding in veterinary R&D, the growing practice of treating pets like humans, and the wider application of artificial intelligence in vet diagnostics. Key trends during this period are projected to revolve around monoclonal antibody treatments creation, applications of artificial intelligence in vet diagnostics, telemedicine incorporation in dermatology, wearable devices for tracking symptoms, advanced allergen-focused immunotherapy, and mobile apps for tracking treatments.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/canine-atopic-dermatitis-global-market-report

What Are the Core Competitive Drivers in the Canine Atopic Dermatitis Industry?
The canine atopic dermatitis market is experiencing growth due to the escalating instances of skin allergies in dogs. Such allergies are abnormal immune reactions to allergens like food, pollen, or flea bites, causing symptoms including skin irritation, redness, and itching. Contributing to the increase in skin allergies is the heightened exposure of dogs to environmental pollutants and allergens, prompting intensified immune responses and skin irritation. Therapies for canine atopic dermatitis are beneficial because they reduce inflammation, control itching, and halt secondary infections, promoting the comfort and skin health of dogs. The National Institutes of Health (NIH) reported in January 2024 that 7,915 dog owners, representing 28.7%, stated their dogs had a history of skin issues. This prevalence consistently grew with age, beginning at 7% in puppies and escalating to 37% in older dogs. As such, the rising cases of skin allergies in dogs are stimulating the expansion of the canine atopic dermatitis market. Additionally, the canine atopic dermatitis market is poised for growth due to the surge in pet ownership. Owning a pet refers to the responsibility of caring for a domestic animal, such as a dog, cat, bird, or another companion animal, as part of a family. The increase in pet ownership is facilitated by the growing humanization of pets as they're treated as family members, encouraging the demand for companionship and emotional support. Addressing canine atopic dermatitis provides benefits to pets, including relief from chronic inflammation and itching, improvement in skin health, and enhancement in overall comfort and quality of life. The American Pet Products Association (APPA) reported in April 2025 that 94 million US households, or 71%, had a pet in 2025, a boost from 86.9 million US households (66%) that had a pet in 20232024. Consequently, the surge in pet ownership is propelling the development of the canine atopic dermatitis market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25717&type=smp

Which Canine Atopic Dermatitis Market Segment Is Projected to See the Fastest Growth?
The canine atopic dermatitis market covered in this report is segmented -

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products
2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds
3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications
4) By Route Of Administration: Oral, Topical, Injectable
5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:
1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone
2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine
3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil
4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies
5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

Which Trends Are Opening New Opportunities in the Canine Atopic Dermatitis Market?
A significant focus of major corporations functioning in the canine atopic dermatitis industry is to gain regulatory clearances, allowing their treatments to be globally adopted and made widely available. Such permissions are granted by governmental health agencies, only once businesses can demonstrate that their medical products have been stringently tested and meet safety, efficiency, and quality requirements. For instance, in September 2024, U.S.-based Elanco Animal Health Inc., an animal health-focused pharmaceutical firm, got the FDA's approval for Zenrelia. This orally administered JAK inhibitor for canines with atopic and allergic dermatitis is offered once daily. This breakthrough approval for Zenrelia paves the way for enhanced management of canines suffering from itchy skin due to chronic, acute, or seasonal inflammations. It works at the itch source, hindering the routes triggering allergic itching and so halting the itch-scratch cycle. From the first dose, Zenrelia shows clear improvements and helps reduce chances of recurrence of itching, a common issue seen in many dogs treated with competitor JAK inhibitors.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25717&type=smp

Who Are the Leaders in the Canine Atopic Dermatitis Market?
Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill's Pet Nutrition Inc., IDEXX Laboratories Inc., Royal Canin SAS, Ceva Santé Animale S.A., Boragen, Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Antech Diagnostics Inc., Vetoquinol S.A., Heska Corporation, Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Bioceltix S.A., Nextmune AB, OKAVA Pharmaceuticals Inc

Which Regional Canine Atopic Dermatitis Markets Offer the Greatest Growth Potential?
North America was the largest region in the canine atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the canine atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.